Fulcrum Therapeutics Executive Compensation Details
Ticker: FULC · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Fulcrum Therapeutics DEF 14A shows exec comp details for FY24, including equity awards for Gould & Sapir.
AI Summary
Fulcrum Therapeutics, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on the change in fair value of outstanding equity awards granted in prior years for individuals like Robert J. Gould and Alex Sapir, as well as vesting dates for awards granted and vested in the covered year.
Why It Matters
This filing provides transparency into how Fulcrum Therapeutics compensates its top executives, which can influence investor decisions and perceptions of the company's financial health and management strategy.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not inherently present new financial risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation data.)
- 20250430 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Filer
- Robert J. Gould (person) — Executive
- Alex Sapir (person) — Executive
- Bryan Stuart (person) — Executive
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, including the election of directors and executive compensation.
Who are the key individuals whose compensation is detailed in this filing?
The filing mentions Robert J. Gould, Alex Sapir, and Bryan Stuart in the context of executive compensation and equity awards.
What specific compensation elements are highlighted for the fiscal year 2024?
The filing details information regarding the change in fair value of outstanding equity awards granted in prior years, and vesting dates for equity awards granted and vested in the covered year.
When was Fulcrum Therapeutics, Inc. incorporated?
Fulcrum Therapeutics, Inc. was incorporated in Delaware (DE).
What is the business address and phone number for Fulcrum Therapeutics, Inc.?
The business address is 26 Landowne Street, Cambridge, MA 02139, and the business phone number is 617-651-8851.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 by Robert J. Gould regarding Fulcrum Therapeutics, Inc. (FULC).